4 Science Park
About Precipio DiagnosticsPrecipio is the only diagnostics company to address the challenges of disease misdiagnosis, and bring a solution to the clinical world. We have successfully combined the experience, knowledge and expertise of academic-level pathology, with commercial-level service. Physicians around the world benefit from direct access to the highest quality of diagnostic support, coupled with rapid and efficient service, needed to battle cancer.
CEO: Ilan Danieli
CSO: Jeffrey Sklar
Please click here for Precipio job opportunities.
17 articles with Precipio Diagnostics
Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
Kathy LaPorte brings 30-year track record of VC success financing and operating innovative biopharma, diagnostics and healthcare companies
Here’s a roundup of biopharma companies that have announced hiring trends since the beginning of the year.
Trials underway at five laboratories and two diagnostic equipment companies
New test fulfills promise of liquid biopsies to cost effectively monitor patients.
First post-merger quarter to turn the corner and demonstrate growth.
The adoption of liquid biopsies is expected to revolutionize cancer care, with an estimated market of $26B annually.
Precipio Commences Validation Study of Proprietary IV-Cell Cytogenetics Media at University of Pe...
1/22/2018The market for cytogenetics media is estimated to exceed $100M annually.
The company expects revenue growth to increase through 2019 as a result.
Study further shows ~73% of cases which academic pathologists determined were previously misdiagnosed, have definite or possible material impact on patient treatment plans.
Precipio Launches its Second New ICE-COLD PCR Targeted Enrichment Kit to Identify Mutations in Lung Cancer Using Liquid (Blood) Biopsies on Sanger Sequencing Platforms
As part of the transformation of ICP to be platform-agnostic, this kit has been adapted to be used on Sanger Sequencing platforms, a widely used DNA sequencing method in molecular diagnostics.
Commercialization plans include third-party validation of the media, alongside discussions with potential industry players to acquire product rights and associated IP.
Precipio to Announce Third Quarter 2017 Financial Results and Provide a Company Update on Monday, November 20, 2017 at 4:05pm Eastern Time
Management will host a conference call on Tuesday, November 21, 2017 at 9:00am to review financial results and provide a corporate update.
Precipio Diagnostics And Transgenomic, Inc. Announce Experts From Yale And Harvard Joining New Scientific Advisory Board To Support Merged Company’s Growth Initiatives